Table 3.
The side effects of pemetrexed maintenance therapy of advanced lung adenocarcinoma following combination chemotherapy of nedaplatin and pemetrexed
| Side effects | Toxicity grade (WHO criteria)
|
|||
|---|---|---|---|---|
| I | II | III | IV | |
| Neutropenia | 12 (31.6%) | 4 (10.5%) | 4 (10.5%) | 0 |
| Thrombocytopenia | 5(13.2%) | 4 (10.5%) | 0 | 0 |
| Hemoglobin reduction | 10 (26.3%) | 6 (15.8%) | 2 (5.5%) | 0 |
| Nausea/vomiting | 11 (28.9%) | 5 (13.2%) | 0 | 0 |
| Allergic reactions | 0 | 0 | 0 | 0 |
| Liver damage | 4 (10.5%) | 0 | 0 | 0 |
| Renal impairment | 0 | 0 | 0 | 0 |
| Hair loss | 9 (23.7%) | 3 (7.9%) | 0 | 0 |
Abbreviation: WHO, World Health Organization.